Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
ZyVersa Therapeutics, Inc. (ZVSA) had Return on Tangible Equity of 168.91% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-19.81M |
|
-- |
|
-- |
|
$20.75M |
|
$-20.75M |
|
$0.09M |
|
$-20.66M |
|
$-20.66M |
|
$-19.81M |
|
$-19.81M |
|
$-19.81M |
|
$-19.81M |
|
$-20.75M |
|
$-20.75M |
|
7.74M |
|
7.74M |
|
$-2.56 |
|
$-2.56 |
|
| Balance Sheet Financials | |
$1.00M |
|
-- |
|
$0.04M |
|
$1.04M |
|
$12.77M |
|
-- |
|
-- |
|
$12.77M |
|
$-11.73M |
|
$-11.73M |
|
$-11.73M |
|
8.10M |
|
| Cash Flow Statement Financials | |
$-4.70M |
|
-- |
|
$3.70M |
|
$1.53M |
|
$0.53M |
|
$-1.00M |
|
$0.21M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.08 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.70M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
168.91% |
|
|
Return on Tangible Equity |
168.91% |
-1903.90% |
|
168.91% |
|
$-1.45 |
|
$-0.61 |
|
$-0.61 |
|